

# Trilotab 30 mg chewable tablets for dogs

Authorised

- Trilostane

## Product identification

**Medicine name:**

Trilotab 30 mg chewable tablets for dogs

---

**Active substance:**

Trilostane

---

**Target species:**

Dog

---

**Route of administration:**

Oral use

---

## Product details

**Active substance and strength:**

Trilostane

30.00 milligram(s) / 1.00 Tablet

---

**Pharmaceutical form:**

Chewable tablet

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QH02CA01

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Latvia

---

**Available in:**

Latvia

---

**Package description:**

Available only in [Latvian](#)

Available only in [Latvian](#)

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Hybrid application - change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)

---

**Marketing authorisation holder:**

CP-Pharma Handelsgesellschaft mbH

---

**Marketing authorisation date:**

27/07/2023

---

**Manufacturing sites for batch release:**

CP-Pharma Handelsgesellschaft mbH

Symbiotica Speciality Ingredients Sdn. Bhd.

---

**Responsible authority:**

Food And Veterinary Service

---

**Authorisation number:**

V/DCP/23/0040

---

**Date of authorisation status change:**

27/07/2023

---

**Reference member state:**

Netherlands

---

**Procedure number:**

NL/V/0373/002

---

**Concerned member states:**

Austria Belgium Czechia Denmark Estonia Finland France Germany  
Hungary Ireland Italy Latvia Lithuania Poland Portugal Slovakia Spain  
Sweden United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to  
[www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

Combined File of all Documents

English (PDF)

Published on: 22/08/2023

Updated on: 13/03/2026

[Download](#)

PuAR Trilotab NL\_V\_0373\_001-005\_DC 2023-08.pdf